<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 53-year-old woman began taking felbamate for uncontrolled <z:hpo ids='HP_0002384'>complex partial seizures</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Four months later, she developed <z:mp ids='MP_0002899'>fatigue</z:mp> and ecchymotic <z:mp ids='MP_0001212'>skin lesions</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Laboratory studies revealed very severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>There have been an additional nine reported cases of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> in the setting of felbamate treatment </plain></SENT>
<SENT sid="4" pm="."><plain>The association between felbamate and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> has resulted in a joint recommendation by the US Food and Drug Administration and the manufacturer of felbamate, Carter-Wallace, Inc., for the immediate withdrawal of patients from treatment with felbamate </plain></SENT>
</text></document>